Abstract
Multiple Sclerosis is a chronic inflammatory demyelinating disorder of the central nervous system. 1H-MRS provides us with additional information on the chemical pathology within the brain and spinal cord in MS patients, when compared to conventional MRI. This has enhanced our understanding of the pathogenesis and natural history in multiple sclerosis. It has proved a useful biomarker of neurodegeneration, as reflected by a decrease in the levels of the neuronal marker, N-acetylaspartate. Changes in choline and myo-inositol have also informed us of the importance of monitoring changes in myelin damage and repair and of the extent of gliosis. This chapter will provide an overview of 1H-MRS in the brain and spinal cord in clinical and preclinical studies in multiple sclerosis. We will also discuss the future potential of 1H-MRS in multiple sclerosis and its promising applications.
References
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700–722
Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6:903–912
Ebers GC, Daumer M (2008) Natural history of MS. Eur J Neurol 15:881–882
Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O’Riordan JI (2013) Changing face of multiple sclerosis in the United kingdom 1990-2010. An incidence and prevalence study. J Neurol Neurosurg Psychiatry 84:e2
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jette N, Pringsheim T, Marrie RA (2013) Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 40:195–210
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517
Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55:671–676
Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112(Pt 6):1419–1428
Vukusic S, Confavreux C (2003) Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206:135–137
Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, Nyland HI (2001) Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 7:59–65
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA Jr, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83:278–286
Koch M, Kingwell E, Rieckmann P, Tremlett H (2010) The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1039–1043
Koch M, Kingwell E, Rieckmann P, Tremlett H (2009) The natural history of primary progressive multiple sclerosis. Neurology 73:1996–2002
Andersson PB, Waubant E, Gee L, Goodkin DE (1999) Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol 56:1138–1142
Lassmann H, VAN Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8:647–656
Lassmann H, Bruck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218
Ebers GC (2004) Natural history of primary progressive multiple sclerosis. Mult Scler 10(Suppl 1):8–13, discussion S13-5
Benedict RH, Fazekas F (2009) Benign or not benign MS: a role for routine neuropsychological assessment? Neurology 73:494–495
Stys PK, Zamponi GW, VAN Minnen J, Geurts JJ (2012) Will the real multiple sclerosis please stand up? Nat Rev Neurosci 13:507–514
Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189
Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192:393–404
Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K, Lassmann H (1994) Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117(Pt 6):1311–1322
Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164–174
Lassmann H (2011) Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol 37:698–710
Geurts JJ, Stys PK, Minagar A, Amor S, Zivadinov R (2009) Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 282:12–20
Lassmann H (2014) Mechanisms of white matter damage in multiple sclerosis. Glia 62(11):1816–1830
Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52:61–76
Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247–269
Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R (2008) Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci 274:42–44
Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M (2010) A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol 67:376–383
Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438–444
Gilmore CP, Donaldson I, Bo L, Owens T, Lowe J, Evangelou N (2009) Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry 80:182–187
Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O (2011) The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 122:155–170
Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089–1104
Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, Aloisi F, Reynolds R (2010) A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 68:477–493
Filippi M, Rocca MA, DE Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68:1514–1520
Seewann A, Vrenken H, Kooi EJ, VAN DER Valk P, Knol DL, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ (2011) Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Mult Scler 17:1202–1210
DE Stefano N, Filippi M (2007) MR spectroscopy in multiple sclerosis. J Neuroimaging 17(Suppl 1):31S–35S
Gass A, Richards TL (2013) Serial proton magnetic resonance spectroscopy of normal-appearing gray and white matter in MS. Neurology 80:17–18
Lin A, Ross BD, Harris K, Wong W (2005) Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2:197–214
Arnold DL, Matthews PM, Francis G, Antel J (1990) Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 14:154–159
Miller DH, Thompson AJ, Filippi M (2003) Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 250:1407–1419
Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, Inglese M, Guttmann CR, Horsfield MA, Filippi M (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7:615–625
Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81:89–131
DE Stefano N, Filippi M, Miller D, Pouwels PJ, Rovira A, Gass A, Enzinger C, Matthews PM, Arnold DL (2007) Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69:1942–1952
Moore GR, Laule C (2012) Neuropathologic correlates of magnetic resonance imaging in multiple sclerosis. J Neuropathol Exp Neurol 71:762–778
Muhlert N, Atzori M, DE Vita E, Thomas DL, Samson RS, Wheeler-Kingshott CA, Geurts JJ, Miller DH, Thompson AJ, Ciccarelli O (2014) 2014. Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry 85(8):833–839
Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D (2005) Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain 128:1016–1025
VAN Horssen J, Witte ME, Ciccarelli O (2012) The role of mitochondria in axonal degeneration and tissue repair in MS. Mult Scler 18:1058–1067
Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289–298
Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI (1993) Detection of myelin breakdown products by proton magnetic resonance spectroscopy. Lancet 341:630–631
Solanky BS, Abdel-Aziz K, Yiannakas MC, Berry AM, Ciccarelli O, Wheeler-Kingshott CA (2013) In vivo magnetic resonance spectroscopy detection of combined glutamate-glutamine in healthy upper cervical cord at 3T. NMR Biomed 26:357–366
Ciccarelli O, Altmann DR, Mclean MA, Wheeler-Kingshott CA, Wimpey K, Miller DH, Thompson AJ (2010) Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 74:721–727
Ciccarelli O, Toosy AT, DE Stefano N, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2010) Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci 30:15030–15033
Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ (2005) MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53:256–266
Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Mclean MA, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2006) Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 253:224–230
Chard DT, Griffin CM, Mclean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH (2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125:2342–2352
Kirov II, Tal A, Babb JS, Herbert J, Gonen O (2013) Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology 80:39–46
Miller TR, Mohan S, Choudhri AF, Gandhi D, Jindal G (2014) Advances in multiple sclerosis and its variants: conventional and newer imaging techniques. Radiol Clin North Am 52:321–336
Wattjes MP, Harzheim M, Lutterbey GG, Klotz L, Schild HH, Traber F (2007) Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28:1517–1522
Fernando KT, Mclean MA, Chard DT, Macmanus DG, Dalton CM, Miszkiel KA, Gordon RM, Plant GT, Thompson AJ, Miller DH (2004) Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 127:1361–1369
Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB (1995) High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 64:742–748
Inglese M, Li BS, Rusinek H, Babb JS, Grossman RI, Gonen O (2003) Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50:190–195
Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, Bruck W (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20:1619–1627
Miller DH (2014) 2014. Magnetic resonance spectroscopy: a possible in vivo marker of disease progression for multiple sclerosis? JAMA Neurol 71(7):828–830
Pan JW, Hetherington HP, Vaughan JT, Mitchell G, Pohost GM, Whitaker JN (1996) Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1T. Magn Reson Med 36:72–77
Caramanos Z, Narayanan S, Arnold DL (2005) 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 128:2483–2506
Rooney WD, Goodkin DE, Schuff N, Meyerhoff DJ, Norman D, Weiner MW (1997) 1H MRSI of normal appearing white matter in multiple sclerosis. Mult Scler 3:231–237
Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW (2000) 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 6:148–155
Filippi M, Rocca MA (2005) MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol 252(Suppl 5):v16–v24
Geurts JJ, Reuling IE, Vrenken H, Uitdehaag BM, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ (2006) MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 55:478–483
Lucchinetti C, Bruck W (2004) The pathology of primary progressive multiple sclerosis. Mult Scler 10(Suppl 1):S23–S30
Filippi M, Rovaris M, Rocca MA (2004) Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. Mult Scler 10(Suppl 1):S36–S44, discussion S44-5
Rovaris M, Bozzali M, Santuccio G, Ghezzi A, Caputo D, Montanari E, Bertolotto A, Bergamaschi R, Capra R, Mancardi G, Martinelli V, Comi G, Filippi M (2001) In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 124:2540–2549
Narayanan S, DE Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979–986
Ciccarelli O, Thomas DL, DE Vita E, Wheeler-Kingshott CA, Kachramanoglou C, Kapoor R, Leary S, Matthews L, Palace J, Chard D, Miller DH, Toosy AT, Thompson AJ (2013) 2013. Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol 74(2):301–305
Sajja BR, Wolinsky JS, Narayana PA (2009) Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 19:45–58
Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, Cavillon G, Rogemond V, Confavreux C, Honnorat J, Giraudon P (2010) Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 133:2578–2591
Rovira A, Alonso J (2013) 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin N Am 23:459–474
Majos C, Aguilera C, Alonso J, Julia-Sape M, Castaner S, Sanchez JJ, Samitier A, Leon A, Rovira A, Arus C (2009) Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 30:544–551
Moore F, Okuda DT (2009) Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 73:1714
Stromillo ML, Giorgio A, Rossi F, Battaglini M, Hakiki B, Malentacchi G, Santangelo M, Gasperini C, Bartolozzi ML, Portaccio E, Amato MP, DE Stefano N (2013) Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology 80:2090–2094
Sbardella E, Tomassini V, Stromillo ML, Filippini N, Battaglini M, Ruggieri S, Ausili Cefaro L, Raz E, Gasperini C, Sormani MP, Pantano P, Pozzilli C, De Stefano N (2011) Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 17:1432–1440
Wattjes MP, Harzheim M, Lutterbey GG, Bogdanow M, Schmidt S, Schild HH, Traber F (2008) Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 50:123–129
Kapeller P, Brex PA, Chard D, Dalton C, Griffin CM, Mclean MA, Parker GJ, Thompson AJ, Miller DH (2002) Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 8:207–210
Narayana PA (2005) Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 15:46S–57S
Achtnichts L, Gonen O, Rigotti DJ, Babb JS, Naegelin Y, Penner IK, Bendfeldt K, Hirsch J, Amann M, Kappos L, Gass A (2013) Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. Eur J Radiol 82:e848–e852
Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI (2004) Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 62:624–627
Lassmann H (2013) Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 333:1–4
Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree BA, Sampat M, Hauser SL, Nelson SJ, Pelletier D (2014) 2014. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol 71(7):840–847
Sajja BR, Narayana PA, Wolinsky JS, Ahn CW (2008) Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 14:73–80
DE Stefano N, Bartolozzi ML, Guidi L, Stromillo ML, Federico A (2005) Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci 233:203–208
Matthews PM, Arnold DL (2001) Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Curr Opin Neurol 14:279–287
Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12:295–302
DE Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL (1995) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38:901–909
DE Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL (1997) Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 49:1138–1141
Aboul-Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W (2010) Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One 5:e11625
Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, Mclean MA, Miller DH, Thompson AJ (2005) Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 62:569–573
Tellez N, Alonso J, Rio J, Tintore M, Nos C, Montalban X, Rovira A (2008) The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology 50:17–23
Langdon DW (2011) Cognition in multiple sclerosis. Curr Opin Neurol 24:244–249
Calabrese M, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Romualdi C, Rinaldi L, Perini P, Gallo P (2010) Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology 74:321–328
Sicotte NL, Kern KC, Giesser BS, Arshanapalli A, Schultz A, Montag M, Wang H, Bookheimer SY (2008) Regional hippocampal atrophy in multiple sclerosis. Brain 131:1134–1141
Gadea M, Martinez-Bisbal MC, Marti-Bonmati L, Espert R, Casanova B, Coret F, Celda B (2004) Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 127:89–98
Neale JH, Olszewski RT, Zuo D, Janczura KJ, Profaci CP, Lavin KM, Madore JC, Bzdega T (2011) Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 118:490–498
Rahn KA, Watkins CC, Alt J, Rais R, Stathis M, Grishkan I, Crainiceau CM, Pomper MG, Rojas C, Pletnikov MV, Calabresi PA, Brandt J, Barker PB, Slusher BS, Kaplin AI (2012) Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc Natl Acad Sci U S A 109:20101–20106
Marliani AF, Clementi V, Albini Riccioli L, Agati R, Carpenzano M, Salvi F, Leonardi M (2010) Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 31:180–184
Ciccarelli O, Wheeler-Kingshott CA, Mclean MA, Cercignani M, Wimpey K, Miller DH, Thompson AJ (2007) Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 130:2220–2231
Blamire AM, Cader S, Lee M, Palace J, Matthews PM (2007) Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy. Magn Reson Med 58:880–885
De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121(Pt 8):1469–1477
Wheeler-Kingshott CA, Stroman PW, Schwab JM, Bacon M, Bosma R, Brooks J, Cadotte DW, Carlstedt T, Ciccarelli O, Cohen-Adad J, Curt A, Evangelou N, Fehlings MG, Filippi M, Kelley BJ, Kollias S, MacKay A, Porro CA, Smith S, Strittmatter SM, Summers P, Thompson AJ, Tracey I (2014) The current state-of-the-art of spinal cord imaging: applications. Neuroimage 84:1082–1093
Abdel Aziz K, Solanky B, Wheeler-Kingshott C, Cawley N, Yiannakas M, Thompson A, Ciccarelli O. (2013) Evidence for early neuronal damage in the cervical cord of patients with primary progressive MS. ECTRIMS. Multiple Sclerosis J 2013. Abstract No: 197
Stroman PW, Wheeler-Kingshott C, Bacon M, Schwab JM, Bosma R, Brooks J, Cadotte D, Carlstedt T, Ciccarelli O, Cohen-Adad J, Curt A, Evangelou N, Fehlings MG, Filippi M, Kelley BJ, Kollias S, MacKay A, Porro CA, Smith S, Strittmatter SM, Summers P, Tracey I (2014) The current state-of-the-art of spinal cord imaging: methods. Neuroimage 84:1070–1081
Bellenberg B, Busch M, Trampe N, Gold R, Chan A, Lukas C (2013) 1H-magnetic resonance spectroscopy in diffuse and focal cervical cord lesions in multiple sclerosis. Eur Radiol 23:3379–3392
Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N, Perreau-Lenz S, Hansson AC, Krumm B, Kiefer F, Spanagel R, Mann K, Ende G, Sommer WH (2012) Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry 71:1015–1021
Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18:21–29
Lee MR, Denic A, Hinton DJ, Mishra PK, Choi DS, Pirko I, Rodriguez M, Macura SI (2012) Preclinical 1H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis 4:1787–1804
Chen CC, Zechariah A, Hsu YH, Chen HW, Yang LC, Chang C (2008) Neuroaxonal ion dyshomeostasis of the normal-appearing corpus callosum in experimental autoimmune encephalomyelitis. Exp Neurol 210:322–330
Brenner RE, Munro PM, Williams SC, Bell JD, Barker GJ, Hawkins CP, Landon DN, McDonald WI (1993) The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 29:737–745
Rigotti DJ, Inglese M, Kirov II, Gorynski E, Perry NN, Babb JS, Herbert J, Grossman RI, Gonen O (2012) Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis. Neurology 78:1383–1389
Denic A, Pirko I, Wootla B, Bieber A, Macura S, Rodriguez M (2012) Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis. Brain Pathol 22:698–708
Kan HE, Techawiboonwong A, VAN Osch MJ, Versluis MJ, Deelchand DK, Henry PG, Marjanska M, VAN Buchem MA, Webb AG, Ronen I (2012) Differences in apparent diffusion coefficients of brain metabolites between grey and white matter in the human brain measured at 7T. Magn Reson Med 67:1203–1209
Wood ET, Ronen I, Techawiboonwong A, Jones CK, Barker PB, Calabresi P, Harrison D, Reich DS (2012) Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy. J Neurosci 32:6665–6669
Hattingen E, Magerkurth J, Pilatus U, Hubers A, Wahl M, Ziemann U (2011) Combined 1H and 31P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis. NMR Biomed 24:536–546
Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ (2010) MR spectroscopic imaging of glutathione in the white and gray matter at 7T with an application to multiple sclerosis. Magn Reson Imaging 28:163–170
Carvalho AN, Lim JL, Nijland PG, Witte ME, Van Horssen J (2014) Glutathione in multiple sclerosis: More than just an antioxidant? Mult Scler. 20:1425–1431
Bhattacharyya PK, Phillips MD, Stone LA, Bermel RA, Lowe MJ (2013) Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS. AJNR Am J Neuroradiol 34:1733–1739
Hock A, Wilm B, Zandomeneghi G, Ampanozi G, Franckenberg S, De Zanche N, Nordmeyer-Maßner J, Spyros S. Kollias, Kramer T, Thali M, Ernst M, and Henning A. (2014) Detection of GABA, Aspartate and Glutathione in the Human Spinal Cord. ISMRM. Abstract No: 1712
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Cawley, N., Ciccarelli, O. (2016). MR Spectroscopy in Multiple Sclerosis. In: Öz, G. (eds) Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-319-33555-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-33555-1_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33553-7
Online ISBN: 978-3-319-33555-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)